glp-1 agonist cardiovascular outcomes in major trials with receptor agonists Cardiovascular Effects of Glucagon-Like Peptide-1

We confirmed the robustness of our findings for the composite outcomes, as complementary analyses using both a Fine-Gray model and a cause specific hazard model with time varying inverse probability-of-death censoring weights yielded consistent results on both relative and absolute scales (supplementary figures S5 and S7)

[DOI] [PubMed] [Google Scholar] 43.Frias JP, et al

64 In contrast with prior anti-obesity medications, concerns about suicide intention have not been confirmed for GLP-1 RA therapy

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin

GLP-1 receptor agonists: Dual systems of care in 2026 GLP-1 receptor agonists have undergone one of the most significant identity shifts in modern pharmacotherapy

While initial effects at 3 months were minimal, sustained reductions at later time points suggest a potentially durable effect on BMI (Figure 2)